BioInfra Co., Ltd.
Financials
Valuation Metrics
BioInfra Co., Ltd.'s Market Cap is ₩65B. At end of 2025 it was ₩230B. Ranked #2403 of 2,410 in KR market (top 100%), #1626 of 1,631 on KOSDAQ (top 100%), #230 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 100%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.47B KRW | KR#2,403/2,410 Sec#230/231 |
| Revenue | 25.62B KRW | KR#2,082/2,410 Sec#147/231 |
| Net Income | -8.29B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 34.19B KRW | KR#2,303/2,410 Sec#213/231 |
| Net Assets | 12.60B KRW | KR#2,348/2,410 Sec#222/231 |
| Employees | 132 | KR#1,424/2,410 Sec#114/231 |
| Value | ||
| P/B | 0.51x | KR#853/2,410 Sec#39/231 |
| P/S | 0.25x | KR#516/2,410 Sec#11/231 |
| FCF Yield | -43.61% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -65.79% | KR#2,302/2,410 Sec#207/231 |
| ROA | -24.24% | KR#2,267/2,410 Sec#186/231 |
| Op. Margin | -20.63% | KR#2,122/2,410 Sec#147/231 |
| Revenue Growth | 4.69% | KR#1,209/2,410 Sec#119/231 |
| Financial Health | ||
| Debt Ratio | 171.38% | KR#2,000/2,410 Sec#212/231 |
| Total Debt | 12.70B KRW | KR#1,542/2,410 Sec#136/231 |
| FCF | -2.82B KRW | KR#1,376/2,410 Sec#107/231 |
| Cash | 2.83B KRW | KR#2,175/2,410 Sec#207/231 |
| Current Ratio | 0.58x | KR#2,086/2,410 Sec#198/231 |
| Dividend | ||
| Div. Growth | -25.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -71.99% | KR#2,305/2,410 Sec#220/231 |
| 1M Return | 93.45% | KR#5/2,410 Sec#1/231 |
| From 52W High | -75.48% | KR#2,231/2,410 Sec#201/231 |
| 1Y MDD | -88.68% | KR#2,385/2,410 Sec#225/231 |
| Trading | ||
| Volume | 249,677 shares | KR#398/2,410 Sec#43/231 |
| Trading Value | 341.6M KRW | KR#1,106/2,410 Sec#123/231 |
| Foreign Own. | 2.68% | KR#1,391/2,410 Sec#128/231 |
| Per Share | ||
| EPS | -1,704 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,590 KRW | KR#1,951/2,410 Sec#154/231 |
Company Info
The company was established in 2007 as a Contract Research Organization (CRO) and listed on the KOSDAQ market in 2023 as a small and medium-sized venture company. Its main businesses include bioequivalence tests for generic medicines, Phase 1 clinical trials for incrementally modified drugs, clinical trials for regulatory approval, immunoanalysis, and pharmaceutical quality testing. The company holds six domestic and international patents in analysis technology and automation, including for tube opening/closing devices and dispensing systems in Korea, the U.S., and Japan. Bioinfra, founded in 2007, is headquartered in Gyeonggi-do, Yongin-si.